Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2019 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (123)	2/23/2019 5:57:48 PM
From: BulbaMan	2 Recommendations Recommended By Steve Lokness The Dodgy Ticker Respond to of 280

Thanks Ashley, I wouldn’t call it modesty, just realizing that the Immune Design buyout is another example of what biotech investing is about. Mostly duds (e.g., CFRX) but a big winner will more than compensate for quite a few losers. Now that Merck, with its substantial resources, is behind the Immune Design drug that produced a complete response for my friend with Merkel cell carcinoma, I’m hopeful it will save many more lives. Peace & good health, Bulba